Lymphoma, Large B-Cell, Diffuse Clinical Trials

5 recruiting

Frequently Asked Questions

Common questions about Lymphoma, Large B-Cell, Diffuse clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 110 of 10 trials

Recruiting
Phase 1Phase 2

A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma

Lymphoma, Non-HodgkinLymphoma, B-CellLymphoma, Large B-Cell, Diffuse
Janssen Research & Development, LLC439 enrolled31 locationsNCT05421663
Recruiting
Phase 2

A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

Lymphoma, Large B-Cell, Diffuse
Merck Sharp & Dohme LLC594 enrolled112 locationsNCT06890884
Recruiting
Phase 2

A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma

LymphomaLymphoma, Large B-Cell, Diffuse
Jennifer Crombie, MD41 enrolled3 locationsNCT05800366
Recruiting
Phase 1Phase 2

Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors

Breast CancerLiver CancerNon-small Cell Lung Cancer (NSCLC)+10 more
Essen Biotech85 enrolled1 locationNCT07410494
Recruiting
Phase 1

A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies

Lymphoma, B-CellChronic Lymphocytic Leukemia (CLL)Lymphoma, Non-Hodgkin (NHL)+1 more
Umoja Biopharma106 enrolled8 locationsNCT06528301
Recruiting
Not Applicable

Reduced-Dose Apixaban and Rivaroxaban Versus Low-Molecular-Weight Heparin in Patients With Hematologic Malignancies

LymphomaLeukemiaMultiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma+4 more
Medical University of Gdansk100 enrolled1 locationNCT07270263
Recruiting

Pragmatic Geriatric Assessment Before CAR-T or Bispecific Antibody Therapy to Predict Side Effects and Outcomes in Older Patients (GA-ACT Trial)

Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), LymphomaCART TherapyBispecific Antibody+1 more
University of Zurich208 enrolled2 locationsNCT07309497
Recruiting
Not Applicable

Randomised Controlled Trial of Artificial Intelligence-assisted Health Education

LeukaemiaLymphomaMultiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma
Zhongnan Hospital196 enrolled1 locationNCT07305337
Recruiting
Phase 1Phase 2

A Phase I/II Trial of ALETA-001 for the Treatment of Participants With B-cell Malignancies

Lymphoma, Non-HodgkinLymphoma, B-CellLarge B-cell Lymphoma+3 more
Cancer Research UK84 enrolled7 locationsNCT06045910
Recruiting
Not Applicable

CD70-targeted immunoPET Imaging of Malignant Cancers

LymphomaRenal CancerMantle Cell Lymphoma+4 more
RenJi Hospital300 enrolled1 locationNCT06852638